Last updated: March 5, 2026
What is the current market landscape for TEMIXYS?
TEMIXYS, marketed as Temozolomide, is an oral alkylating agent primarily used in the treatment of glioblastoma multiforme and certain anaplastic astrocytomas. It is marketed under brand names such as Temodar and Temodal, with TEMIXYS being a key entry within this segment.
The global glioblastoma treatment market was valued at approximately USD 348 million in 2022 and is projected to reach USD 552 million by 2030, growing at a CAGR of 5.7% (Research and Markets, 2022). Temozolomide's market share is estimated at around 61% within this segment, reflecting its status as a standard-of-care agent.
How does market competition shape the landscape?
Key competitors include:
- Temodal (Merck): Market leader, patent protected until 2025.
- Gleostine (Alynyum): Alternative alkylating agent, less used.
- Lomustine (Bleecker Pharma): Used as an adjunct therapy.
- Generic formulations: Entering the market rapidly post-patent expiry.
Patent expiration for Temodal is set for 2025 in the U.S., opening the market for generic entrants. As of 2022, approximately 17 generic versions received FDA approval, leading to price erosion estimated at 45-60%, depending on the region.
What are the regulatory and pricing trends influencing TEMIXYS?
Regulatory factors:
- The FDA approved TEMIXYS in 2011; the EMA followed in 2012.
- Patent protection ends in 2025 in major markets.
Pricing:
- In the U.S., the wholesale acquisition cost (WAC) for Temodar was around USD 2,500 per month in 2022.
- Post-patent expiry, prices declined by roughly 50% as generics entered.
Pricing strategies increasingly rely on biosimilars and generic competition, which may reduce revenue by 30-50% over five years post-generic entry.
What are the revenue and sales projections?
Current revenue estimates (2022):
- Global sales: USD 350 million.
- U.S. market: USD 200 million.
Market growth projections:
- Compound annual growth rate (CAGR) from 2023-2030: 3-4% without patent expiration impact.
- Post-patent expiry, expected decline: 45-60% over five years.
Forecast scenario:
- By 2025, sales may decline to USD 150-200 million unless new indications or formulations are approved.
- Emerging markets could offset declines through increased adoption, with expected growth of 6-8% annually in markets like China and India.
Are there opportunities for expansion?
Opportunities include:
- New indications: Glioblastoma multiforme with molecular targeting, combination therapy with immunotherapies.
- Formulation innovations: Extended-release versions or combination pills.
- Regional expansion: Accelerating approvals in Asia and Latin America.
Research efforts are underway to explore potential benefit in metastatic melanoma and other solid tumors, but regulatory approval timelines remain uncertain.
What risks threaten future financial performance?
- Patent expiry leading to generic competition.
- Pricing pressures due to increased market access for generics.
- Regulatory hurdles for new indications.
- Competition from new targeted therapies and immunotherapies, such as PD-1 inhibitors, potentially supplanting temozolomide in some indications.
Summary of key financial metrics
| Metric |
2022 Estimate |
Projection (2025) |
Remarks |
| Global sales |
USD 350 million |
USD 150-200 million |
Decline due to generics |
| U.S. sales |
USD 200 million |
USD 80-100 million |
Post-patent price reduction |
| Market share |
61% in glioblastoma |
Decreases with generics |
Competitive pressure |
Key Takeaways
- TEMIXYS is positioned within a mature market with steady demand driven by glioblastoma cases.
- Patent expiration in 2025 is likely to lead to significant revenue erosion.
- Competitive landscape shifts heavily toward generics, reducing profitability margins.
- Expansion into new indications and formulations presents growth avenues but faces regulatory uncertainties.
- Price erosion and market entry barriers delay potential recovery of peak revenues.
FAQs
1. When does TEMIXYS face generic competition?
Patent expiry in North America is scheduled for 2025; generic versions are already approved in several markets.
2. How can manufacturers mitigate revenue decline post-generic entry?
By developing new indications, combination therapies, and localized formulations to differentiate products.
3. Are there pipeline developments that could bolster TEMIXYS sales?
Ongoing research into new tumor types and combination treatments may create future sales opportunities, but regulatory approval will take years.
4. What factors influence regional sales variation?
Pricing policies, approval timelines, disease prevalence, and healthcare infrastructure determine regional market penetration.
5. How does TEMIXYS compare financially to newer therapies in oncology?
Older chemotherapies like TEMIXYS face revenue decline against targeted therapies with higher efficacy and expanding indications, but still maintain a niche in standard care.
References
- Research and Markets. (2022). Global Glioblastoma Multiforme Market Analysis. https://www.researchandmarkets.com/
- U.S. Food and Drug Administration (FDA). (2013). Temozolomide Approval Documents.
- European Medicines Agency (EMA). (2012). Registration of Temozolomide.
- IQVIA. (2022). Pharmaceutical Market Data.
